(Reuters) – Eli Lilly (LLY) expects sales of popular weight-loss drug Zepbound and related diabetes treatment Mounjaro to miss Wall Street expectations in the fourth quarter, but forecasts 2025 revenue largely above estimates.
As of 10:03:13 AM EST. Market Open.
The company said on Tuesday it expects $3.5 billion in Mounjaro sales in the fourth quarter, and $1.9 billion for Zepbound. Analysts had expected the drugs to bring in $5.35 billion and $2.08 billion, respectively, according to data compiled by LSEG.
“Our previous guidance had anticipated even faster acceleration of growth for the quarter. That, in addition to lower-than-expected channel inventory at year-end, contributed to our Q4 results,” CEO David Ricks said.
Lilly said it expects 2025 sales between $58 billion and $61 billion. Analysts were expecting revenue of $58.52 billion.
(Reporting by Bhanvi Satija in Bengaluru; Editing by Shounak Dasgupta)
